123 related articles for article (PubMed ID: 37777120)
1. Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy.
Khan MA; Singh D; Jameel M; Maurya SK; Singh S; Akhtar K; Siddique HR
Toxicol Appl Pharmacol; 2023 Nov; 478():116699. PubMed ID: 37777120
[TBL] [Abstract][Full Text] [Related]
2. Antiandrogen enzalutamide induced genetic, cellular, and hepatic damages: amelioration by triterpene Lupeol.
Khan MA; Singh D; Fatma H; Akhtar K; Arjmand F; Maurya S; Siddique HR
Drug Chem Toxicol; 2023 Mar; 46(2):380-391. PubMed ID: 35188013
[TBL] [Abstract][Full Text] [Related]
3. Role of lupeol in chemosensitizing therapy-resistant prostate cancer cells by targeting MYC, β-catenin and c-FLIP: in silico and in vitro studies.
Maurya SK; Fatma H; Maurya AK; Mishra N; Siddique HR
In Silico Pharmacol; 2022; 10(1):16. PubMed ID: 36072559
[TBL] [Abstract][Full Text] [Related]
4. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
Siddique HR; Mishra SK; Karnes RJ; Saleem M
Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
[TBL] [Abstract][Full Text] [Related]
5. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X
Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003
[TBL] [Abstract][Full Text] [Related]
7. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells.
de Las Pozas A; Reiner T; De Cesare V; Trost M; Perez-Stable C
Sci Rep; 2018 Sep; 8(1):13146. PubMed ID: 30177856
[TBL] [Abstract][Full Text] [Related]
10. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
[TBL] [Abstract][Full Text] [Related]
11. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
[TBL] [Abstract][Full Text] [Related]
13. A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer.
Mourkioti I; Polyzou A; Veroutis D; Theocharous G; Lagopati N; Gentile E; Stravokefalou V; Thanos DF; Havaki S; Kletsas D; Panaretakis T; Logothetis CJ; Stellas D; Petty R; Blandino G; Papaspyropoulos A; Gorgoulis VG
J Exp Clin Cancer Res; 2023 Jul; 42(1):187. PubMed ID: 37507762
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it.
Wang Y; Chen J; Wu Z; Ding W; Gao S; Gao Y; Xu C
Br J Pharmacol; 2021 Jan; 178(2):239-261. PubMed ID: 33150960
[TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
16. Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer.
Wu M; Zhang R; Zhang Z; Zhang N; Li C; Xie Y; Xia H; Huang F; Zhang R; Liu M; Li X; Cen S; Zhou J
Elife; 2023 Jan; 12():. PubMed ID: 36656639
[TBL] [Abstract][Full Text] [Related]
17. Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers.
Maxwell PJ; McKechnie M; Armstrong CW; Manley JM; Ong CW; Worthington J; Mills IG; Longley DB; Quigley JP; Zoubeidi A; de Bono JS; Deryugina E; LaBonte MJ; Waugh DJJ
Mol Cancer Res; 2022 Jun; 20(6):841-853. PubMed ID: 35302608
[TBL] [Abstract][Full Text] [Related]
18. Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer.
Cerasuolo M; Maccarinelli F; Coltrini D; Mahmoud AM; Marolda V; Ghedini GC; Rezzola S; Giacomini A; Triggiani L; Kostrzewa M; Verde R; Paris D; Melck D; Presta M; Ligresti A; Ronca R
Cancer Res; 2020 Apr; 80(7):1564-1577. PubMed ID: 32029552
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
20. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
